Cargando…

P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria

POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: 1. To compare; 2. performance characteristics of lateral flow assay (Aspergillus galactomannan LFA, Immy, USA) in comparison with ELISA (Platelia™ Aspergillus antigen, Bio-Rad, France) for detection of galactomannan antigen in b...

Descripción completa

Detalles Bibliográficos
Autores principales: Padaki, Priyadarshini, Savio, Jayanthi, Ramachandran, Priya, Krishna, Bhuvana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515866/
http://dx.doi.org/10.1093/mmy/myac072.P436
_version_ 1784798584646926336
author Padaki, Priyadarshini
Savio, Jayanthi
Ramachandran, Priya
Krishna, Bhuvana
author_facet Padaki, Priyadarshini
Savio, Jayanthi
Ramachandran, Priya
Krishna, Bhuvana
author_sort Padaki, Priyadarshini
collection PubMed
description POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: 1. To compare; 2. performance characteristics of lateral flow assay (Aspergillus galactomannan LFA, Immy, USA) in comparison with ELISA (Platelia™ Aspergillus antigen, Bio-Rad, France) for detection of galactomannan antigen in blood and BAL samples from suspected cases of Invasive Aspergillosis (IA); 3. turn-around time for reporting and the cost per test for both the methods: 1. To identify new host factors for categories of IA as per BM-AspICU (Hamam et al. Ann. Intensive Care, 2021) guidelines. METHODS: A total of 50 consecutive leftover samples (30 blood and 20 BAL) received for testing by Galactomannan assay by ELISA method were included. LFA and ELISA were performed as per manufacturers’ instructions. Results were recorded using the Digital Reader provided which gives readings as Positive ≥0.5 and <0.5 Negative. Additionally, results were read visually by two different people and graded as 0 (negative), 1+ (very faint band), 2+ (faint band), and 3+ (strong band). The values obtained by ELISA were reported as Galactomannan Index. Results of LFA and ELISA were compared. Patient profiles were studied to identify the possible and probable cases of IA as per BM-AspICU guidelines. RESULTS: Overall, 92% samples (n = 46) were positive with ELISA. Results of LFA and ELISA were comparable in 68% samples (n = 34). For all except two samples, visual readings of LFA (5 with 3+, 12 with 2 + and 19 with 1 + readings) correlated with digital readings. Sensitivity of LFA was 73.9% (95% CI). Applying BM-AspICU criteria, 28% (n = 14) were categorized as probable, 64% (n = 32) as possible cases of IA and 8% (n = 4) as NO IA. A total of 12 patients had classical host factors, 42% (n = 21) had other risk factors and we were able to identify 16% (n = 8) cases with new risk factors which were CNS involvement/brain injury/hemorrhage on mechanical ventilation. Clinical features were present in all of these 58% (n = 29) cases whereas radiological imaging was done in only 25 cases out of which 28% (n = 14) were positive. BM-AspICU criteria require ≥2 mycological criteria, but only two of the BAL samples were culture positive for Aspergillus species. These criteria could not be strictly applied to most patients in our study since invasive procedures such as BAL was not done, instead, blood was sent for galactomannan detection. The average turn-around time was 3-7 days for ELISA since the test was run twice a week whereas it was 5-24 h for the LFA. The pre-processing of samples and time required to perform the procedure for both the assays are similar. The cost per test for ELISA was Rs.1675/- as against LFA for Rs.750/-. CONCLUSION: LFA for galactomannan detection is an easier to perform, cost-effective method for diagnosis of IA as compared with ELISA. LFA overcomes the difficulty of insufficient volume of calibrators and controls provided with the ELISA kit. Useful especially for patients admitted in ICU where reports can be issued on the same day instead of batch testing. Identification of new risk factors and inclusion of the same under guidelines is essential to suspect and send samples for testing for early initiation of treatment.
format Online
Article
Text
id pubmed-9515866
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95158662022-09-28 P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria Padaki, Priyadarshini Savio, Jayanthi Ramachandran, Priya Krishna, Bhuvana Med Mycol Oral Presentations POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: 1. To compare; 2. performance characteristics of lateral flow assay (Aspergillus galactomannan LFA, Immy, USA) in comparison with ELISA (Platelia™ Aspergillus antigen, Bio-Rad, France) for detection of galactomannan antigen in blood and BAL samples from suspected cases of Invasive Aspergillosis (IA); 3. turn-around time for reporting and the cost per test for both the methods: 1. To identify new host factors for categories of IA as per BM-AspICU (Hamam et al. Ann. Intensive Care, 2021) guidelines. METHODS: A total of 50 consecutive leftover samples (30 blood and 20 BAL) received for testing by Galactomannan assay by ELISA method were included. LFA and ELISA were performed as per manufacturers’ instructions. Results were recorded using the Digital Reader provided which gives readings as Positive ≥0.5 and <0.5 Negative. Additionally, results were read visually by two different people and graded as 0 (negative), 1+ (very faint band), 2+ (faint band), and 3+ (strong band). The values obtained by ELISA were reported as Galactomannan Index. Results of LFA and ELISA were compared. Patient profiles were studied to identify the possible and probable cases of IA as per BM-AspICU guidelines. RESULTS: Overall, 92% samples (n = 46) were positive with ELISA. Results of LFA and ELISA were comparable in 68% samples (n = 34). For all except two samples, visual readings of LFA (5 with 3+, 12 with 2 + and 19 with 1 + readings) correlated with digital readings. Sensitivity of LFA was 73.9% (95% CI). Applying BM-AspICU criteria, 28% (n = 14) were categorized as probable, 64% (n = 32) as possible cases of IA and 8% (n = 4) as NO IA. A total of 12 patients had classical host factors, 42% (n = 21) had other risk factors and we were able to identify 16% (n = 8) cases with new risk factors which were CNS involvement/brain injury/hemorrhage on mechanical ventilation. Clinical features were present in all of these 58% (n = 29) cases whereas radiological imaging was done in only 25 cases out of which 28% (n = 14) were positive. BM-AspICU criteria require ≥2 mycological criteria, but only two of the BAL samples were culture positive for Aspergillus species. These criteria could not be strictly applied to most patients in our study since invasive procedures such as BAL was not done, instead, blood was sent for galactomannan detection. The average turn-around time was 3-7 days for ELISA since the test was run twice a week whereas it was 5-24 h for the LFA. The pre-processing of samples and time required to perform the procedure for both the assays are similar. The cost per test for ELISA was Rs.1675/- as against LFA for Rs.750/-. CONCLUSION: LFA for galactomannan detection is an easier to perform, cost-effective method for diagnosis of IA as compared with ELISA. LFA overcomes the difficulty of insufficient volume of calibrators and controls provided with the ELISA kit. Useful especially for patients admitted in ICU where reports can be issued on the same day instead of batch testing. Identification of new risk factors and inclusion of the same under guidelines is essential to suspect and send samples for testing for early initiation of treatment. Oxford University Press 2022-09-20 /pmc/articles/PMC9515866/ http://dx.doi.org/10.1093/mmy/myac072.P436 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Padaki, Priyadarshini
Savio, Jayanthi
Ramachandran, Priya
Krishna, Bhuvana
P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria
title P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria
title_full P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria
title_fullStr P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria
title_full_unstemmed P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria
title_short P436 A study to compare detection of Aspergillus galactomannan in patients with clinically suspected invasive Aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria
title_sort p436 a study to compare detection of aspergillus galactomannan in patients with clinically suspected invasive aspergillosis using the lateral flow assay (lfa) in comparison with enzyme linked immunosorbent assay (elisa) and identification of new risk factors as per bm-aspicu criteria
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515866/
http://dx.doi.org/10.1093/mmy/myac072.P436
work_keys_str_mv AT padakipriyadarshini p436astudytocomparedetectionofaspergillusgalactomannaninpatientswithclinicallysuspectedinvasiveaspergillosisusingthelateralflowassaylfaincomparisonwithenzymelinkedimmunosorbentassayelisaandidentificationofnewriskfactorsasperbmaspicucriteria
AT saviojayanthi p436astudytocomparedetectionofaspergillusgalactomannaninpatientswithclinicallysuspectedinvasiveaspergillosisusingthelateralflowassaylfaincomparisonwithenzymelinkedimmunosorbentassayelisaandidentificationofnewriskfactorsasperbmaspicucriteria
AT ramachandranpriya p436astudytocomparedetectionofaspergillusgalactomannaninpatientswithclinicallysuspectedinvasiveaspergillosisusingthelateralflowassaylfaincomparisonwithenzymelinkedimmunosorbentassayelisaandidentificationofnewriskfactorsasperbmaspicucriteria
AT krishnabhuvana p436astudytocomparedetectionofaspergillusgalactomannaninpatientswithclinicallysuspectedinvasiveaspergillosisusingthelateralflowassaylfaincomparisonwithenzymelinkedimmunosorbentassayelisaandidentificationofnewriskfactorsasperbmaspicucriteria